Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers,…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $24.06B | +9.9% | $5.24B | $2.14 | -52.9% | 66.3% | 26.6% |
| Q4 2025 Dec 2025 | $24.56B | — | $5.12B | $2.10 | — | 67.6% | 22.8% |
| Q3 2025 Sep 2025 | $23.99B | — | $5.15B | $2.12 | — | 69.6% | 29.6% |
| Q2 2025 Jun 2025 | $23.74B | — | $5.54B | $2.29 | — | 67.9% | 28.3% |
| Q1 2025 Mar 2025 | $21.89B | — | $11.00B | $4.54 | — | 66.4% | 28.3% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Can the upcoming Johnson & Johnson Earnings report justify the healthcare giant's premium valuation after a massive defensive stock rally?
